ESR1 and Gynecomastia: Notably, its ability to block estrogen receptors in the breast while acting as an estrogen agonist in other tissues (such as bone) provides a therapeutic advantage in managing gynecomastia without adversely affecting other estrogen-dependent tissues [41].